Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.72 |
| ▸ | HTR1A | P08908 | 17/20 | 0.70 |
| ▸ | HTR1D | P28221 | 17/20 | 0.70 |
| ▸ | HTR1B | P28222 | 17/20 | 0.70 |
| ▸ | DRD2 | P14416 | 9/20 | 0.66 |
| ▸ | HTR7 | P34969 | 9/20 | 0.66 |
| ▸ | DRD3 | P35462 | 9/20 | 0.66 |
| ▸ | HTR2A | P28223 | 8/20 | 0.66 |
| ▸ | HTR2B | P41595 | 8/20 | 0.66 |
| ▸ | HTR2C | P28335 | 7/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.65 |
| ▸ | HTR6 | P50406 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884073 | 0.89 | HTR1A (0.57) | CYP2C9HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL2880730 | 0.89 | HTR1A (0.57) | CYP2C9HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL3997450 | 0.86 | SIGMAR1 (0.53) | CYP2C9HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL2880743 | 0.85 | SIGMAR1 (0.53) | CYP2C9HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL2878129 | 0.85 | HTR1A (0.57) | CYP2C9HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL2880901 | 0.83 | CYP2C9 (0.79) | CYP2C9HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL2878229 | 0.83 | HTR1A (1.00) | CYP2C9HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL2884757 | 0.83 | CYP2C9 (0.79) | CYP2C9HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL2882531 | 0.81 | HTR1A (0.77) | CYP2C9HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL2878464 | 0.81 | CYP2C9 (0.50) | CYP2C9HTR1AHTR1DHTR1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | GLAXO GROUP LIMITED | 2010-08-12 | — | — | US | disclosed |
| US-7732600-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| EP-2145622-A1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | Glaxo Group Limited (GB) | 2010-01-20 | — | — | EP | disclosed |
| US-20090312546-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2009-12-17 | — | — | US | disclosed |
| EP-1876174-B1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LTD (GB) | 2009-11-11 | — | — | EP | disclosed |
| US-7592346-B2 | e.g. 3-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-1,3-oxazolidin-2-one; serotonin receptor antagonist and inverse agonists, agonists or partial agonists, serotonin reuptake inhibitor; antidepressant, anxiolytic agent | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7459456-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2008-12-02 | — | — | US | disclosed |
| US-20080280919-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2008-11-13 | — | — | US | disclosed |
| EP-1646613-B1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LTD (GB) | 2008-03-19 | — | — | EP | disclosed |
| EP-1876174-A1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| US-7279481-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2007-07-19 | — | — | US | disclosed |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| EP-1646613-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005014552-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | OPRK1, OPRL1, OPRD1 | CYP2C9 2221/4885HTR1A 5/4885HTR1D 6/4885 |
| US-20090312546-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | CYP2C9 1201/4885HTR1A 1/4885HTR1D 2/4885 |
| US-20080280919-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | CYP2C9 1313/4885HTR1A 1/4885HTR1D 2/4885 |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | CYP2C9 1149/4885HTR1A 1/4885HTR1D 2/4885 |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | HTR1A, HTR1D, HTR1F | CYP2C9 1149/4885HTR1A 1/4885HTR1D 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.